Application of conflictology methods for evaluating physical protection systems effectiveness

At present, physical protection of nuclear material and nuclear facilities is actual. For the implementation of physical protection, Physical Protection System (PPS) is created at nuclear facilities. We all know that the most important characteristic is effectiveness of physical protection systems. PPS effectiveness value is determined by the probability that reaction forces can stop and intercept the intruder. There are many methods to assess the effectiveness of PPS. However, not all methods can provide an accurate quantitative assessment of the effectiveness of security systems. This work presents an approach for assessing the resistance of PPS to emerging threat (that is, the intruder to act against items of physical protection).Based on the fact that different processes are subject to universal physical laws and principles of development, a parallel between the concepts of Conflictology field was established to describe the interaction in the system "intruder against PPS"

Использование микроконтроллера ESP32 совместно с гироприборами MPU-6050 и BNO055 при создании самобалансирующих роботов

Статья посвящена анализу возможностей электронных приборов, таких как гироскоп, акселерометр, магнитометр. Приводятся результаты тестирования и действующие алгоритмы. Анализируются возможности их применения в разных вариантах расчетов. Делаются выводы по развитию возможностей и устранению недостатков полученной комплексной системы позиционирования робота

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, reliable assessment is essential. In this review, we propose a new concept, namely the implementation of a risk-management framework that enables the use of sTILs as a stratification factor in clinical trials. We present the design of a biomarker risk-mitigation workflow that can be applied to any biomarker incorporation in clinical trials. We demonstrate the implementation of this concept using sTILs as an integral biomarker in a single-center phase II immunotherapy trial for metastatic TNBC (TONIC trial, NCT02499367), using this workflow to mitigate risks of suboptimal inclusion of sTILs in this specific trial. In this review, we demonstrate that a web-based scoring platform can mitigate potential risk factors when including sTILs in clinical trials, and we argue that this framework can be applied for any future biomarker-driven clinical trial setting